205 related articles for article (PubMed ID: 33728417)
1. Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves.
Nawas MT; Shah GL; Feldman DR; Ruiz JD; Robilotti EV; Aslam AA; Dundas M; Kamboj M; Barker JN; Cho C; Chung DJ; Dahi PB; Giralt SA; Gyurkocza B; Lahoud OB; Landau HJ; Lin RJ; Mailankody S; Palomba ML; Papadopoulos EB; Politikos I; Ponce DM; Sauter CS; Shaffer BC; Scordo M; van den Brink MRM; Perales MA; Tamari R
Transplant Cell Ther; 2021 May; 27(5):438.e1-438.e6. PubMed ID: 33728417
[TBL] [Abstract][Full Text] [Related]
2. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
[TBL] [Abstract][Full Text] [Related]
3. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy.
Ljungman P; Mikulska M; de la Camara R; Basak GW; Chabannon C; Corbacioglu S; Duarte R; Dolstra H; Lankester AC; Mohty M; Montoto S; Murray J; Peffault de Latour R; Snowden JA; Yakoub-Agha I; Verhoeven B; Kröger N; Styczynski J;
Bone Marrow Transplant; 2020 Nov; 55(11):2071-2076. PubMed ID: 32404975
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience.
Maurer K; Saucier A; Kim HT; Acharya U; Mo CC; Porter J; Albert C; Cutler C; Antin JH; Koreth J; Gooptu M; Romee R; Wu CJ; Soiffer RJ; Nikiforow S; Jacobson C; Ho VT
Blood Adv; 2021 Feb; 5(3):861-871. PubMed ID: 33560397
[TBL] [Abstract][Full Text] [Related]
5. Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients.
Al-Ramahi JS; Shahzad M; Li K; DeJarnette S; Chaudhary SG; Lutfi F; Ahmed N; Balusu R; Bansal R; Abdelhakim H; Shune L; Singh AK; Abhyankar SH; McGuirk JP; Mushtaq MU
Leuk Lymphoma; 2023 Dec; 64(12):1981-1991. PubMed ID: 37574842
[TBL] [Abstract][Full Text] [Related]
6. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey.
Passweg JR; Baldomero H; Ciceri F; Corbacioglu S; de la Cámara R; Dolstra H; Glass B; Greco R; McLornan DP; Neven B; de Latour RP; Perić Z; Ruggeri A; Snowden JA; Sureda A
Bone Marrow Transplant; 2023 Jun; 58(6):647-658. PubMed ID: 36879108
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy.
Yurkiewicz I; Craig J; Muffly L
Curr Hematol Malig Rep; 2020 Jun; 15(3):187-193. PubMed ID: 32358681
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T Cell Therapy Recipients with Pre-Cellular Therapy SARS-CoV-2 Infection.
Nimgaonkar I; Yoke LH; Roychoudhury P; Flaherty PW; Oshima MU; Weixler A; Gauthier J; Greninger AL; Mielcarek M; Boeckh M; Liu C; Hill JA
Clin Infect Dis; 2024 Mar; ():. PubMed ID: 38427848
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection.
Shah N; Dahi PB; Ponce DM; Sauter CS; Shaffer BC; Chung DJ; Politikos I; Lin RJ; Giralt SA; Papanicolaou G; Ramanathan LV; Perales MA; Kamboj M; Shah GL; Gyurkocza B
Transplant Cell Ther; 2022 Jan; 28(1):55.e1-55.e5. PubMed ID: 34649021
[TBL] [Abstract][Full Text] [Related]
12. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
13. Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy.
Camargo JF; Mendoza MA; Lin R; Moroz IV; Anderson AD; Morris MI; Natori Y; Natori A; Raja M; Lekakis L; Beitinjaneh A; Jimenez A; Goodman M; Wang T; Komanduri KV; Pereira D
Transpl Infect Dis; 2021 Aug; 23(4):e13625. PubMed ID: 33896088
[TBL] [Abstract][Full Text] [Related]
14. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Hay KA; Gauthier J; Hirayama AV; Voutsinas JM; Wu Q; Li D; Gooley TA; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Schoch G; Chapuis AG; Till BG; Kiem HP; Ramos JD; Shadman M; Cassaday RD; Acharya UH; Riddell SR; Maloney DG; Turtle CJ
Blood; 2019 Apr; 133(15):1652-1663. PubMed ID: 30728140
[TBL] [Abstract][Full Text] [Related]
16. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
[TBL] [Abstract][Full Text] [Related]
17. Healthcare Utilization is High in Adult Patients Relapsing after Allogeneic Hematopoietic Cell Transplantation.
Langston JA; Sundaram V; Periyakoil VS; Muffly L
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1659-1665. PubMed ID: 30959162
[TBL] [Abstract][Full Text] [Related]
18. Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation.
Worel N; Shaw BE; Aljurf M; Koh M; Seber A; Weisdorf D; Schwartz J; Galeano S; Kodera Y; Eldridge PW; Hashmi S; Atsuta Y; Szer J; Saber W; Niederwieser D; Greinix HT;
Transplant Cell Ther; 2021 Mar; 27(3):270.e1-270.e6. PubMed ID: 33781537
[TBL] [Abstract][Full Text] [Related]
19. Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment.
Hu G; Cheng Y; Zuo Y; Chang Y; Suo P; Jia Y; Lu A; Wang Y; Jiao S; Zhang L; Sun Y; Yan C; Xu L; Zhang X; Liu K; Wang Y; Zhang L; Huang X
Front Immunol; 2022; 13():915590. PubMed ID: 35734165
[TBL] [Abstract][Full Text] [Related]
20. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation.
Shah GL; DeWolf S; Lee YJ; Tamari R; Dahi PB; Lavery JA; Ruiz J; Devlin SM; Cho C; Peled JU; Politikos I; Scordo M; Babady NE; Jain T; Vardhana S; Daniyan A; Sauter CS; Barker JN; Giralt SA; Goss C; Maslak P; Hohl TM; Kamboj M; Ramanathan L; van den Brink MR; Papadopoulos E; Papanicolaou G; Perales MA
J Clin Invest; 2020 Dec; 130(12):6656-6667. PubMed ID: 32897885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
